

Advances in Acute Pain Management


Lee Wilson
Consultant Pharmacist
Bassetlaw Hospital

What's Coming Up?

- 'Advances' in Acute Pain Management
 - Novel ways of administering old medicines
 - Some new therapies and evidence
- What do we already know about acute pain management?
 - Multimodal analgesia
- Brief overview of PONV prophylaxis

Why Manage Acute Pain?

- To prevent negative psychological and physiological consequences
 - Pain and suffering (incl. persistent pain)
 - Pneumonia
 - Impaired GI motility
 - Impaired wound healing
 - Tachycardia/Hypertension
 - Prevent ongoing pain



Incidence of Persistent Pain following Surgical Procedures

Type of Operation	Incidence (%)
Amputation	30 to 85
Thoracotomy	5 to 67
Mastectomy	11 to 57
Cholecystectomy	3 to 56
Inguinal Hernia	0 to 63
Vasectomy	0 to 37
Dental Surgery	5 to 13

Advances in Acute Pain Management

- Slow progress despite considerable Pharma investment
 - Potential they may withdraw completely?
- Most new analgesic therapies look to reduce the adverse effects of current therapies¹



Recent Analgesic Developments

- Paracetamol IV
 - (Propacetamol)
 - Perfalgan
- Diclofenac IV (Dyloject)*
- COXIBs
 - Celecoxib
 - Etoricoxib
 - Lumaricoxib
 - Parecoxib (IV)
 - Rofecoxib
 - Valdecoxib
- Targinact
 - Oxycodone plus Naloxone MR
- Tapentadol
 - New opioid analgesic
?effect on NeuP
- Ionsys
 - Fentanyl iontophoretic transdermal system
- Depodur
 - Epidural MR morphine

Paracetamol IV

- Reduce dose in low weight patients
- Manufacturers state: <50kg, use 15mg/kg²
- Analgesia not now thought to be blocked by ondansetron³

- We use doses based on weight ranges:

Wt (kg)	<30	30-44	45-50
Dose (mg)	500 tds	500 qds	1000 tds

Dyloject (Diclofenac IV⁴)

- Advantages

- Voltarol requires dilution and buffering before IV admin.
- Onset of action better than with Voltarol (bolus vs 30 min inf.)
- Non-inferiority demonstrated


- Disadvantages

- More expensive than Voltarol*
- Confusion if multiple diclofenac preps kept
- Withdrawn in May 2010 following the presence of white particulate matter^{4a}

Coxibs

- Initially, widely adopted nationally
- Withdrawal of rofecoxib and valdecoxib signalled massive U-turn
- Along with risks, benefits not as pronounced as hoped

- Etoricoxib and lumoxicoxib rarely prescribed
- Note, Pfizer's patent expires in Nov 2014




Updates to the Evidence Base

- Regular Opioids in Post-Operative Pain
 - Evidence base poor but audit data may support use
- Spinal Opioids
- Ketamine
- Clonidine
- Dexamethasone⁴
- Adjuvants for NeuP
 - Gabapentinoids


Dexamethasone

- Widely prescribed for PONV
- Recent meta-analysis⁴:
 - Examined high ($\geq 0.21\text{mg/kg}$), medium (0.11 to 0.2mg/kg) or low ($\leq 0.1\text{mg/kg}$) doses
 - Reduced post-operative pain in the treatment groups
 - Low dose failed to achieve a statistically significant effect on pain at early (0-4h) pain at rest (-0.33 [-0.70 to 0.04])
 - High and medium doses reduced opioid consumption
 - Pre-operative administration appears to produce a more consistent analgesic effect

Epidural Analgesia (incl. PCEA)



Bandolier League Table of Analgesics



- Notes:
 - In single doses, codeine is not an effective analgesic
 - Tramadol 50mg less effective (NNT=8.3)
 - NSAIDs all have similar efficacy (use the safest!)
 - Don't use IM morphine*

Other Potential Options and Future Therapies

- Ketamine (in sub-anaesthetic doses)
- Acupuncture
- Local anaesthetic infusion devices
 - e.g. ON-Q soaker
- Capsaicin
 - Injectable preparation being trialled in post-operative pain
- Patient-controlled regional anaesthesia

So Where Does This Leave Us?



Multimodal Analgesia^{5,6}

Morphine


Reduced doses of each
analgesic

Improved effectiveness
due to synergistic/additive
effects

May reduce severity of
side effects of each drug

NSAIDs⁷,
Paracetamol⁷
Nerve Blocks

Enhanced Recovery



Enhanced Recovery: Anaesthetic Protocol

- Standardised protocol⁸
- Spinal block
 - Epidural/Spinal
- Rationale
 - Blocks autonomic afferent pathways
 - Pain control
 - Reduce dose of inhalational/IV anaesthetics

Enhanced Recovery: Post-Operative Analgesia

- Keep opioids to a minimum
- Avoid PCA
- Epidural < 48 hours
- IV paracetamol/oral NSAIDs
 - NSAIDs - with or after food?

Tried and Tested Therapies

- Prescribe Regularly:
 - Paracetamol
 - NSAIDs (ibuprofen or naproxen - where not contraindicated) in short courses eg. 3/7
- With Strong Opioid prescribed PRN:
 - eg. oral/sc morphine*

- Place for Other Modalities:
 - Nerve Blocks and Epidurals (& PCEA)
 - PCA or Regular Strong Opioids*

*Aim to limit dose esp. in ERAS; Opioid dose may need reducing in elderly, frail and renal pts & increasing for those on regular strong opioids (including IVDUs)

Resources

- Acute Pain Management: Scientific Evidence⁹
- Clinical Pharmacy and Therapeutics
 - Chapter on Pain by R. Knaggs and G. Hobbs
 - Edited by R. Walker and C. Edwards

Family mis-Fortunes

We asked 100 patients what their main concern about post-operative recovery was.

Our survey said....

- 1.**
- 2.**
- 3.**
- 4.**
- 5.**

What do patient's want?

Concerns during post-op recovery¹⁰

Importance of factor		Principal factor
Emesis	40%	72%
Pain/aches	29%	9%
Dysphoria	16%	4%
Extra cost	10%	2%
Mental acuity	5%	4%

Apfel Risk Scoring System¹¹

- Patient Scores One Point for Each Risk Factor
 - Female Gender
 - Non-Smoking Status
 - Post-Operative Opioid Use
 - Previous History of PONV or Motion Sickness
- Good Correlation between Incidence of PONV and Number of Risk Factors

Correlation between risk factors and PONV

Risk Score	0	1	2	3	4
PONV Risk	10%	20%	40%	60%	80%
Level	Low	Low	Med	High	High

Apfel suggested that any patient scoring 2 or more should receive prophylaxis

Consensus Guidelines (Gan *et al*, 2003¹²)

Risk Score	0	1	2	3	4
PONV Risk	10%	20%	40%	60%	80%
Antiemetics	0	0	1/2/3	2/3	2/3

Evidence Base – Impact¹³

- Large Patient Numbers (n=5199)
- All High Risk Patients
 - risk score=2 or more
- Most (n=4123) were randomised to received combination of 6 prophylactic interventions
 - 64 different treatment combinations (2^6)
 - Remainder received comb.'s of first 4 interventions

Evidence Base – Impact¹³

- Ondansetron 4mg
- Dexamethasone 4mg
- Droperidol 1.25mg
- Propofol
- Nitrogen
- Remifentanyl
- No Ondansetron
- No Dexamethasone
- No Droperidol
- Inhaled Anaesthetic
- Nitrous Oxide
- Fentanyl

Evidence Base – Impact¹³

Antiemetic s (number)	0	1	2	3
Incidence of PONV	52	37	28	22

Evidence Base – Impact Trial¹³

- Each agent reduced incidence of PONV by around a quarter (26%)
- No agent was found to be more effective than any other
- Combination of avoiding nitrous oxide and propofol use (TIVA) reduced risk by 26%
- No advantage with remifentanyl

PONV: Summary

- Prophylaxis indicated for high risk patients using a combination of anti-emetics
 - I would suggest all should receive one agent
- There is little to choose between antiemetics used*
- Anti-emetics used for treatment should target a different site of action to those used for prophylaxis
- Sufficient evidence is now available to guide management of PONV
- Prophylaxis is key - Treatment is often difficult: use policies

Take Home Messages

- Multimodal analgesia is still important
- Opioids widely used but low opioid techniques may reduce adverse effects and length of stay
- Modified-release opioids may have a place
- Ketamine may be a useful adjunct in resistant pain cases

Take Home Messages (for discussion)

- Developments in acute pain management are few and far between in recent years
- Acute pain management is often less complex than it is time-consuming*
- Good quality pain assessment is key
 - Along with pain scoring and action when scores are high

Take Home Messages (for discussion)

- Chronic pain patients continue to present some of the biggest challenges
- This includes opioid users
 - If on regular opioids, may need increased PRN doses
 - Recreational users often most difficult to manage
 - Continue regular opioid (nb. Subutex)
 - Baseline analgesia (adding tramadol may help)

References

- 1. Power I. An update on analgesics. BJA 107: 19-24 (via <http://bj.oxfordjournals.org/content/107/1/19.full.pdf>)
- 2. MHRA Drug Safety Update 3(12), July 2010 (via <http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088171>)
- 3. Minville V et al. Ondansetron does not block paracetamol-induced analgesia in a mouse model of fracture pain. BJA 106: 112-8 (via <http://bj.oxfordjournals.org/content/early/2010/10/16/bja.aeq277.full.pdf>)
- 4. North Central London Formulary and Medicines Management Group. Dyloject (diclofenac sodium) for post-operative pain. British Journal of Clinical Pharmacy 2: 43-44 (via http://www.clinicalpharmacy.org.uk/volume1_2/2010/february/drugappraisal.pdf)
- 4a. See <http://www.dyloject.co.uk>
- 5. De Oliveira GS. Perioperative single dose dexamethasone for post-operative pain. Anesthesiology 115(3): 575-88 (via http://www.feinberg.northwestern.edu/anesthesiology/welcome/Anesthesiology_article.pdf)

References

- 5. Kehlet H and Dahl JB. The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. *Anesthesia and Analgesia* 77: 1049-56 (via <http://www.anesthesia-analgesia.org/content/77/5/1048.full.pdf>)
- 6. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. *BJA* 78: 606-17 (via <http://bj.oxfordjournals.org/content/78/5/606.full.pdf>)
- 7. Smith HS. Perioperative intravenous acetaminophen and NSAIDs. *Pain Medicine* 12(6): 961-81
- 8. Kehlet H. Multimodal approach to postoperative recovery. *Curr Opin Crit Care* 15: 355-8 (via [http://www.improvement.nhs.uk/enhancedrecovery2/Portals/2/documents/multimodalapproachtopostoperativererecovery\[1\].pdf](http://www.improvement.nhs.uk/enhancedrecovery2/Portals/2/documents/multimodalapproachtopostoperativererecovery[1].pdf))
- 9. Acute Pain Management: Scientific Evidence (via <http://www.anzca.edu.au/resources/books-and-publications/acutepain.pdf>)

References

- 10. Orkin FK, Anesthesia and Analgesia 1992; 74: S225
- 11. Apfel CC et al. A simplified risk score for the prediction of postoperative nausea and vomiting. Anesthesiology, 91(3): 693-700 (via <http://www.ponv.org>)
- 12. Gan TJ et al. Consensus Guidelines for the management of postoperative nausea and vomiting. Anesthesia and Analgesia, 97(6): 62-71 (via <http://www.ponv.org>)
- 13. Apfel CC et al. A Factorial Trial of Six Interventions for the Prevention of Postoperative Nausea and Vomiting. NEJM 350(24): 2441-2451 (via: <http://www.ponv.org>)